BMS’s Zenbexus meets PFS endpoint in pivotal multiple myeloma trial

BMS’s Zenbexus gained FDA approval in multiple myeloma based on a previous primary endpoint being achieved in the same trial. BMS’s Zenbexus gained FDA approval based on a previous primary endpoint being achieved in the same trial. BMS released the data for the dual primary endpoint in PFS. Credit: nitpicker / Shutterstock.com Bristol Myers Squibb’s (BMS’s) Phase III trial of Zenbexus (iberdomide) has more than doubled progression-free survival (PFS) in patients with multiple myeloma (MM). In the EXCALIBER-RRMM study (NCT04975997), there was a statistically significant improvement in the dual-primary endpoint of PFS, with median PFS of 42 months for patients…

Source: Clinical Trials Arena